To spur innovation and bolster ties with tech giants, Swiss pharma giant Novartis plans to set up innovation labs across the globe to partner with these companies to spur the development of new therapies.
Consumer/Patient Experience Special Feature: Masters Of The Pharma Universe: 4 Databases Every Digital Marketer Must Know
Nearly two-thirds of U.S. senior business decision-makers rank big data/analytics first among the technologies necessary for enhancing the customer experience. A similar number put “improving data analysis capabilities” at the top of their priorities.
According to a drug shortage list provided by the U.S. Food and Drug Administration, there have been more than 100 drugs that have faced shortages during 2018.
Dr. Robert Redfield, the new head of the U.S. Centers for Disease Control and Prevention, boldly predicted in April 2018 that the AIDS epidemic can be defeated by 2025. Merck, Janssen and Gilead Sciences all released clinical data for HIV treatments that could make Redfield’s prediction a reality.
Personalized medicine continues to grow in importance, and having the ability to monitor health data has proven to be a significant desire for people as the number of wearable devices continues to grow.
AstraZeneca’s immunotherapy drug Imfinzi cut the risk of death in patients with mid-stage lung cancer by nearly a third in a closely watched clinical study, reinforcing the case for using the drug in earlier disease.
Morphic Therapeutic Announces $80 Million Financing to Advance Next-Generation Oral Integrin Therapeutics Through Clinical Proof of Concept
Morphic Therapeutic has completed a $80 million Series B financing to fund the biotechnology company’s two lead programs through clinical proof of concept, and to advance multiple other programs into the clinic.
So-called arthroscopic knee surgery is becoming a less common treatment for adults with torn cartilage or painful arthritis as a growing body of evidence shows little benefit from these operations, a U.S. study suggests.
The U.S. Food and Drug Administration approved Boston Scientific Corp.’s drug-coated stent Eluvia to treat narrowed arteries in the leg.
Galera Therapeutics Raises $150 Million for GC4419 Phase 3 Trial and Pre-Commercialization Activities in Lead Indication
Galera Therapeutics Inc.announced that the clinical-stage biotechnology company secured $150 million in a joint, oversubscribed Series C financing and royalty purchase agreement.
Viking Therapeutics Inc.’s shares more than doubled in value after promising data from a mid-stage trial of the company’s fatty liver drug were seen as topping that from larger rival Madrigal Pharmaceuticals.
Following a setback in a chronic obstructive pulmonary disease (COPD) clinical trial in August, AstraZeneca unveiled data from a separate trial that showed the triple combination therapy PT010 outperformed dual-therapy rivals eight of nine times.
If you are a clinical researcher or scientist, you are well-aware of the inefficiencies of current search processes that require hours of time wading through data to find hidden nuggets of valuable info.
Urovant Sciences, a Vivek Ramaswamy company under the Roivant umbrella, filed for an initial public offering (IPO) to raise $150 million.
One in three teen drivers in the U.S. text while driving, new survey data suggests, and the number may be higher in states where teens start driving at younger ages.
With increased access to insurance under the Affordable Care Act (also known as Obamacare), fewer uninsured patients have been hospitalized for serious heart conditions, a U.S. study suggests.
23andMe will no longer provide “outside app developers” access to the company’s raw genetic data, CNBC reported.
Ann Arbor, Mich.-based Esperion Therapeutics reported final results from a long-term safety study of bempedoic acid 180 mg versus placebo in high-risk patients with atherosclerotic cardiovascular disease (ASCVD) whose disease is inadequately controlled by statins.
Pfizer Inc.’s tafamidis reduced the risk of death for patients with a rare and fatal heart disease by around 30 percent, boosting the prospects of what could be a billion-dollar-a-year drug.
The U.S. FDA approved Ortho Dermatologics’ NDA for Altreno (tretinoin 0.05%) lotion, indicated for the topical treatment of acne vulgaris in patients 9 years of age and older.
FDA Accepts Priority Review Of ALXN1210 As Treatment For Patients With Paroxysmal Nocturnal Hemoglobinuria
Alexion Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration accepted for review the company’s Biologics License Application for approval of ALXN1210, an investigational long-acting C5 complement inhibitor, for the treatment of patients with paroxysmal nocturnal hemoglobinuria.